Thrombolysis after acute myocardial infarction

Preview

Physicians know that thrombolysis has marked benefits in patients with certain classic findings after acute myocardial infarction. However, some do not realize that thrombolysis has relatively limited risks and can be administered to many more patients than it is at present. The authors review current indications and contraindications and summarize results of major clinical studies that compare currently available thrombolytic agents.

Additional information

Notes on contributors

Vincent M. Figueredo

Vincent M. Figueredo, MD Thomas M. Amidon, MD Christopher L. Wolfe, MD Dr Figueredo (right) is assistant professor of medicine, Dr Amidon (left) is assistant clinical professor of medicine, and Dr Wolfe (middle) is associate professor of medicine and radiology and associate director, coronary care unit, department of cardiology, University of California, San Francisco, School of Medicine.

Thomas M. Amidon

Vincent M. Figueredo, MD Thomas M. Amidon, MD Christopher L. Wolfe, MD Dr Figueredo (right) is assistant professor of medicine, Dr Amidon (left) is assistant clinical professor of medicine, and Dr Wolfe (middle) is associate professor of medicine and radiology and associate director, coronary care unit, department of cardiology, University of California, San Francisco, School of Medicine.

Christopher L. Wolfe

Vincent M. Figueredo, MD Thomas M. Amidon, MD Christopher L. Wolfe, MD Dr Figueredo (right) is assistant professor of medicine, Dr Amidon (left) is assistant clinical professor of medicine, and Dr Wolfe (middle) is associate professor of medicine and radiology and associate director, coronary care unit, department of cardiology, University of California, San Francisco, School of Medicine.